Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines

Therapeutic Delivery

Volumn 3, Issue 6, 2012, Pages 749-760

  Fujita, Yoshio ^a   Taguchi, Hiroaki ^a  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPID A DERIVATIVE; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VACCINE; VAX 102; VAX 125; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; COMBINATION CHEMOTHERAPY; CROSS PRESENTATION; CROSS REACTION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA A; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINE PRODUCTION;

EID: 84861797388     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.52     Document Type: Review

References (119)

1. Tognotti E. The eradication of smallpox, a success story for modern medicine and public health: What lessons for the future? J. Infect. Dev. Ctries 4(5), 264-266 (2010).
2. Cima G. Rinderpest eradicated. International organizations declare 'cattle plague' dead. J. Am. Vet. Med. Assoc. 239(1), 11-15, (2011).
3. Roberts L. Polio eradication. Looking for a little luck. Science 323(5915), 702-705 (2009).
4. Aylward B, Yamada T. The polio endgame. N. Engl. J. Med. 364(24), 2273-2275 (2011).
5. Zauner W, Lingnau K, Matter F, von Gabain A, Buschle M. Defied synthetic vaccines. Biol. Chem. 382(4), 581-595 (2001).
6. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4), S63-S68 (2005).
7. Aguilar JC, Rodfíguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752-3762 (2007).
8. Guy B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Micro. 5(7), 505-517 (2007).
9. Imler JL, Hoffmann JA. Signaling mechanisms in the antimicrobial host defense of Drosophila. Curr. Opin. Microbiol. 3(1), 16-22 (2000).
10. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782-787 (2000).
11. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1(2), 135-145 (2001).
12. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388(4), 621-625 (2009).
13. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
14. Uematsu S, Jang MH, Chevrier N et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat. Immunol. 7(8), 868-874 (2006).
15. Zhang D, Zhang G, Hayden MS et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303(5663), 1522-1526 (2004).
16. Akira S, Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
17. Sun J, Wiklund F, Zheng SL et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl Cancer Inst. 97(7), 525-532 (2005).
18. Bochud PY, Hersberger M, Taffé P et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 21(4), 441-446 (2007).
19. Sobieszczyk ME, Lingappa JR, McElrath MJ. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr. Opin. HIV AIDS 6(5), 427-434 (2011).
20. Hawn TR, Scholes D, Li SS et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS ONE 4(6), e5990 (2009).
21. Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against Leprosy. J. Immunol. 178(12), 7520-7524 (2007).
22. Misch EA, Macdonald M, Ranjit C et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from Leprosy reversal reaction. PLoS Negl. Trop. Dis. 2(5), e231 (2008).
23. Schroder NW, Diterich I, Zinke A et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J. Immunol. 175(4), 2534-2540 (2005).
24. Hawn TR, Verbon A, Lettinga KD et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' Disease. J. Exp. Med. 198(10), 1563-1572 (2003).
25. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc. Natl Acad. Sci. USA 102(7), 2487-2489 (2005).
26. Zhang Q, Qian FH, Zhou LF et al. Polymorphisms in Toll-like receptor 4 gene are associated with asthma severity but not susceptibility in a Chinese Han population. J. Investig. Allergol. Clin. Immunol. 21(5), 370-377 (2011).
27. Kanagaratham C, Camateros P, Flaczyk A, Radzioch D. Polymorphisms in Toll-like receptor genes and their roles in allergic asthma and atopy. Recent Pat. Inflamm. Allergy Drug Discov. 5(1), 45-56 (2011).
28. Wurfel MM, Gordon AC, Holden TD et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am. J. Respir. Crit. Care Med. 178(7), 710-720 (2008).
29. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals Toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2(12), e1318 (2007).
30. Hawn TR, Misch EA, Dunstan SJ et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur. J. Immunol. 37(8), 2280-2289 (2007).
31. Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25(2), 187-191 (2000).
32. Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol. Immunother. 60(9), 1211-1220 (2011).
33. Wang H, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosinedinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr. Pharm. Des. 11(22), 2889-2907 (2005).
34. Akazawa T, Inoue N, Shime H, Kodama K, Matsumoto M, Seya T. Adjuvant engineering for cancer immunotherapy development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci. 101(7), 1596-1603 (2010).
35. Johansen P, Senti G, Martinez Gomez JM et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy 35(12), 1591-1598 (2005).
36. Metzger JW, Beck-Sickinger AG, Loleit M, Eckert M, Bessler WG, Jung G. Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseu- domonasviridis enhance murine splenocyte proliferation. J. Pept. Sci. 1(3), 184-190 (1995).
37. Langhan B, Braunschweiger I, Schweitzer S et al. Lipidation of T helper sequences from hepatits C virus core significantly enhances T-cell activity in vitro. Immunol. 102(4), 460-465 (2001).
38. Sieling PA, Chung W, Duong BT, Godowski PJ, Modlin RL. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170(1), 194-200 (2003).
39. Takeda K, Akira S. Microbial recognition by Toll-like receptors. J. Dermatol. Sci. 34(2), 73-82 (2004).
40. Sacht G, Märten A, Deiters U et al. Activation of nuclear factor-kB in macrophages by mycoplasmal lipopeptides. Eur. J. Immunol. 28(12), 4207-4212 (1998).
41. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect. Immun. 66(10), 4804-4810(1998).
42. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185(11), 1951-1958 (1997).
43. Jackson DC, Lau YF, Le T et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101(43), 15440-15445 (2004).
44. Zeng W, Eriksson E, Chua B, Grollo L, Jackson DC. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 39(2), 471-480 (2010).
45. Abdel-Aal A-BM, Al-Isae K, Zaman M, Toth I. Simple synthetic Toll-like receptor 2 ligands. Bioorg. Med. Chem. Lett. 21(24), 5863-5865 (2011).
46. Seyberth T, Voss S, Brock P, Wiesmüller K-H, Jung G. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-Activity relationships. J. Med. Chem. 49(5), 1754-1765 (2006).
47. Wu W, Li R, Malladi SS et al. Structure- activity relationships in Toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J. Med. Chem. 53(8), 3198-3213 (2010).
48. Jin MS, Kim SE, Heo JY et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-Acylated lipopeptide. Cell 130(6), 1071-1082 (2007).
49. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-Adjuvanting immunocontraceptive vaccines. J. Immunol. 169(9), 4905-4912 (2002).
50. Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brow LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol. 18(12), 1801-1813 (2006).
51. Hewitt MC, Seeberger PH. Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine. J. Org. Chem. 66(12), 4233-4243 (2001).
52. Buskas T, Thompson P, Boons GJ. Immunotherapy for cancer: Synthetic carbohydrate-based vaccines. Chem. Commun. (Camb.) 36, 5335-5349 (2009).
53. Ingale S, Wolfert MA, Buskas T, Boons G-J. Increasing the antigenicity of synthetic tumor-Associated carbohydrate antigens by targeting Toll-like receptors. Chem. Bio. Chem. 10(3), 455-463 (2009).
54. Ingale S, Wolfert MA, Gaewad J, Buskas T, Boons G-J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3(10), 663-667 (2007).
55. Kaiser A, Gaidzik N, Becker T et al. Fully synthetic vaccines consisting of tumor-Associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. Angew. Chem. Int. Ed. 49(1), 1-6 (2010).
56. Cai H, Huang ZH, Shi L, Zhao YF, Kunz H, Li YM. Towards a fully synthetic MUC1- based anticancer vaccine: Efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Chemistry 17(23), 6396-6406 (2011).
57. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat. Rev. Cancer 4(1), 45-60 (2004).
58. Moyle PM, Toth I. Self-Adjuvanting lipopeptide vaccines. Curr. Med. Chem. 15(5), 506-516 (2008).
59. Zaman M, Abdel-Aal AB, Phillipps KS, Fujita Y, Good MF, Toth I. Structure-Activity relationship of lipopeptide group A streptococcus (GAS) vaccine candidates on Toll-like receptor 2. Vaccine 28(10), 2243-2248 (2010).
60. Zaman M, Abdel-Aal AB, Fujita Y et al. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: Structure-Activity relationship. PLoS One 7(1), e30146 (2012).
61. Abdel-Aal AB, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I. Design of three-component vaccines against group A streptococcal infections: Importance of spatial arrangement of vaccine components. J. Med. Chem. 53(22), 8041-8046 (2010).
62. Beutler B. Endotoxin, Toll-like receptor 4, and the afferent limb of innate immunity. Curr. Opin. Microbiol. 3(1), 23-28 (2000).
63. Ulevitch RJ. Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv. Immunol. 53, 267-289 (1993).
64. Allison AC. Adjuvants and immune enhancement. Int. J. Technol. Assess. Health Care 10(1), 107-120 (1994).
65. Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191-1195 (2009).
66. Qureshi N, Mascagni P, Ribi E, Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595: Purification of the dimethyl derivative by high performance lipid chromatography and complete structural determination. J. Biol. Chem. 260(9), 5271-5278 (1985).
67. Myers K, Trochot AT, Ward J. A critical determination of lipid A endotoxic activity. Cellular and molecular aspects of endotoxin reactions. Proceedings of the 1st Congress of the International Endotoxin Society. San Diego, USA, 9-12 May 1990.
68. Wang Q, Xue J, Guo Z. Synthesis of a monophosphoryl lipid A derivative and its conjugation to a modified form of a tumor-Associated carbohydrate antigen GM3. Chem. Commun. (Camb.) 37, 5536-5537 (2009).
69. Wang Q, Zhou Z, Tang S, Guo Z. Carbohydrate-monophosphoryl lipid A conjugates are fully synthetic self-Adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol. 7(1), 235-240 (2012).
70. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167(4), 1882-1885 (2001).
71. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832), 1099-1103 (2001).
72. Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763-775 (2007).
73. Bargieri DY, Rosa DS, Braga CJ et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella typhimurium FliC flagellin. Vaccine 26(48), 6132-6142 (2008).
74. Braga CJ, Massis LM, Sbrogio-Almeida ME et al. CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 28(5), 1373-1382 (2010).
75. Delaney KD, Phipps JP, Johnson JB, Mizel SB. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol. 23(2), 201-210(2010).
76. Lamb RA, Lai CJ, Choppin PW. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: Colinear and interrupted mRNAs code for overlapping proteins. Proc. Natl Acad. Sci. USA 78(7), 4170-4174 (1981).
77. Fiers W, De Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine 27(45), 6280-6283 (2009).
78. Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201-214 (2008).
79. Talbot HK, Rock MT, Johnson C et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5(12), e14442 (2010).
80. Turley CB, Rupp RE, Johnson C et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29(32), 5145-5152 (2011).
81. Song L, Nakaar V, Kavita U et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: A solution to global pandemic and seasonal needs. PLoS ONE 3(5), e2257 (2008).
82. Song L, Zhang Y, Yun NE et al. Superior efficacy of a recombinant flagellin: H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27(42), 5875-5884 (2009).
83. Treanor JJ, Taylor DN, Tussey L et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28(52), 8268-8274 (2010).
84. Taylor DN, Treanor JJ, Strout C et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29(31), 4897-4902 (2011).
85. Gerster JF, Lindstrom KJ, Miller RL et al. Synthesis and structure-Activity relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 48(10), 3481-3491 (2005).
86. Tomai MA, Gibson SJ, Imbertson LM et al. Immunomodulating and antiviral activities of the imidazoquinolinesS-28463. Antiviral Res. 28(3), 253-264 (1995).
87. Izumi T, Sakaguchi J, Takeshita M et al. 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-Alpha suppressors: Synthesis and structure-Activity relationship of 1-, 2-And 4-substituted 1H-imidazo[4,5-c] quinolines or 1H-imidazo[4,5-c]pyridines. Bioorg. Med. Chem. 11(12), 2541-2550 (2003).
88. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: A novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21(1), 1-14 (1999).
89. Shukla NM, Kimbrell MR, Malladi SS, David SA. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline. Bioorg. Med. Chem. Lett. 19(8), 2211-2214 (2009).
90. Shukla NM, Malladi SS, Day V, David SA. Preliminary evaluation of a 3H-imidazoquinoline library as dual TLR7/ TLR8 antagonists. Bioorg. Med. Chem. 19(12) 3801-3811 (2011).
91. Shukla NM, Malladi SS, Mutz CA, Balakrishna R, David SA. Structure-Activity relationships in human Toll-like receptor 7-Active imidazoquinoline analogues. J. Med. Chem. 53(11), 4450-4465 (2010).
92. Shukla NM, Mutz CA, Ukani R, Warshakoon HJ, Moore DS, David SA. Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. Bioorg. Med. Chem. Lett. 20(22), 6384-6386 (2010).
93. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T Cell responses. J. Immunol. 174(12), 7676-7683 (2005).
94. Wille-Reece U, Flynn BJ, Loré K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102(42), 15190-15194 (2005).
95. Wille-Reece U, Flynn BJ, Loré K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006).
96. Oh JZ, Kurche JS, Burchill MA, Kedl RM. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118(11), 3028-3038 (2011).
97. Shukla NM, Lewis TC, Day TP et al. Toward self-Adjuvanting subunit vaccines: Model peptide and protein antigens incorporating covalently bound Toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21(11), 3232-3236 (2011).
98. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
99. Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol. 37(8), 2063-2074 (2007).
100. Kim D, Kwon S, Rhee JW et al. Production of antibodies with peptide-CpG-DNA liposome complex without carriers. BMC Immunol. 12, 29 (2011).
101. Häcker H, Mischak H, Miethke T et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17(21), 6230-6240 (1998).
102. Raja K, McDonald R, Tuck S, Rodriguez R, Milley B, Traquina P. One-pot synthesis, purification, and formulation of bionanoparticle-CpG oligodeoxynucleotide hepatitis B surface antigen conjugate vaccine via tangential flow filtration. Bioconjug. Chem. 18(2), 285-288 (2007).
103. Heit A, Maurer T, Hochrein H et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-Aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170(6), 2802-2805 (2003).
104. Sandip K. Datta SK, Cho HJ, Takabayashi K, Horner AA, Raz E. Antigen-immunostimulatory oligonucleotide conjugates: Mechanisms and applications. Immunol. Rev. 199, 217-226 (2004).
105. Heit A, Schmitz F, O'Keeffe M et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174(7), 4373-4380 (2005).
106. Khan S, Bijker MS, Weterings JJ et al. Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282(29), 21145-21159 (2007).
107. Teshima R, Okunuki H, Sato Y, Akiyama H, Maitani T, Sawada J. Effect of oral administration of CpG ODN on WBB6F1-W/Wv mice. Allergol. Int. 55(1), 43-48 (2006).
108. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113(2), 235-241 (2004).
109. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113(6), 1144-1151 (2004).
110. Creticos PS, Schroeder JT, Hamilton RG et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1445-1455 (2006).
111. Rafnar T, Griffith IJ, Kuo MC, Bond JF, Rogers BL, Klapper DG. Cloning of Amba I (antigen E), the major allergen family of short ragweed pollen. J. Biol. Chem. 266(2), 1229-1236 (1991).
112. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313-2322 (2005).
113. Zhu Q, Egelston C, Vivekanandhan A et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. Proc. Natl. Acad. Sci. USA. 105(42), 16260-16265 (2008).
114. Zhu Q, Egelston C, Gagnon S et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 609-616 (2010).
115. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
116. Warger T, Osterloh P, Rechtsteiner G et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108(2), 544-550 (2006).
117. Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413-424 (2006).
118. Querec TD, Akondy RS et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2009).
119. Kasturi SP, Skountzou I, Albrecht RA et al. Programing the magnitude and persistence of antibody responses with immunity. Nature 470(7335), 543-547 (2011).